Spironolactone for anemia in children on dialysis
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether spironolactone can help treat anemia in children aged 6-18 who are on hemodialysis. It may improve their response to current anemia treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 6 to 18 years old
- On hemodialysis for at least 6 months, 3 times per week
- Weight between 25 and 110 pounds
- Low potassium level (less than 5.5) and still making urine
- Hemoglobin (red blood cell protein) between 9.5 and 12.5, with low iron stores
- On a stable dose of an anemia medication (EPO) for at least 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
This trial studies whether taking iron by mouth can improve iron levels and anemia (low red blood cell counts) in children with chronic kidney disease. It may help reduce fatigue and support normal blood-making, by comparing different approaches for children who meet specific iron test results.
This trial studies whether spironolactone can improve pulmonary arterial hypertension, a disease that makes the blood vessels in the lungs work too hard. You may be eligible if your condition is confirmed by specific heart-lung pressure tests and your medication plan has been stable for at least 4 weeks.
This trial tests if spironolactone can help children with autism who have a certain genetic change (in the NCOR gene). The study will monitor improvement and safety over time.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This study looks at how well erythropoietin (a drug that helps your body make red blood cells) works for people with end-stage kidney disease who are on regular hemodialysis. It also checks if metabolic syndrome (a group of conditions like high blood sugar, high blood pressure, and extra belly fat) affects how well this drug works.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.